More than 10,000 distinct rare conditions affect hundreds of millions of people worldwide, with rare diseases in the US defined as affecting fewer than 200,000 people3
The European Joint Programme on Rare Diseases (EJP-RD) is launching demonstration projects like EPISTOP-IDeAl, EBStatMax, and Improve PSP to validate innovative statistical methodologies for small population clinical trials1
Innovation projects focus on improving trial design, endpoints, and statistical analysis methods specifically tailored for limited populations in rare diseases1
The Robert A. Winn Excellence in Clinical Trials Award Program trains community-oriented clinical trialists in community engaged trial design and equitable patient recruitment to strengthen rare disease research2
Rare disease research drives broader medical innovation, with insights from rare neurological and genetic disorders informing therapies for more common conditions3
Recent initiatives include iSTORE, which develops innovative statistical methodologies for rare epilepsies using Dravet syndrome as a model, and Evidence RND for ultra-rare neurological diseases1
Philanthropic funding has enabled breakthroughs such as novel drug delivery approaches for diffuse intrinsic pontine glioma (DIPG), resulting in extended survival times and attracting significant venture capital and pharmaceutical investment4
Sources:
1. https://pmc.ncbi.nlm.nih.gov/articles/PMC11077753/
2. https://convention.bio.org/2026-sessions-and-courses/equity-by-design-reimagining-clinical-trials
3. https://acadia.com/en-us/media/perspectives/acadia-stories/when-rare-is-everywhere-why-small-patient-populations-drive-big-progress
4. https://www.insidephilanthropy.com/home/new-wins-for-rare-disease-research-funded-by-philanthropy